What is the Current Status of Lipase Inhibitors in Clinical Research?
Currently, several lipase inhibitors are under investigation in preclinical and early clinical trials. Compounds such as orlistat, originally developed as an anti-obesity drug, have demonstrated anti-cancer activity by inhibiting fatty acid synthase, a key enzyme in lipid metabolism. Other novel inhibitors are being explored for their ability to target specific cancer-related pathways. However, more research is needed to validate their efficacy and safety in larger, more diverse patient populations.
